In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Haemacure Corp.

Division of Angiotech Pharmaceuticals Inc.
www.haemacure.com

Latest From Haemacure Corp.

Haemacure puts up "for sale" sign

Haemacure has put itself up for sale while its hunt for financing continues to be unsuccessful. The Canadian company, which has been seeking cash since the third quarter of last year, will also suspend development of its lead candidate and reduce costs.

Canada Companies

Haemacure makes new appointment to board of directors

The Canadian biotherapeutics company Haemacure has appointed Dr Thomas Lynch to its board of directors. Dr Lynch brings 15 years experience as a research scientist in public, academic and private sectors to the position, and whilst on the board will aid the progression to Phase II/III clinical trials for Haemacure's lead candidate, Hemaseel HMN (fibrin sealant), for biosurgical haemostasis. Dr Lynch currently serves as senior vice-president of compliance, regulatory affair and public policy for Talecris Biotherapeutics; prior to this he was vice-president of regulatory affair and quality assurance at CryoLife.

Companies

Renovo's Juvista succeeds in Phase II, but development plans disappoint

Renovo's scar-healing treatment Juvista (human recombinant TGF beta3) has succeeded in a Phase II study, but details of US development plans for the product have disappointed analysts and investors.

Dermatology Wound Healing & Tissue Repair

Renovo given EU thumbs up for Juvista for Phase III

Renovohas received positive feedback from the EU's CHMPregarding its plans for Phase III development of the scar-reduction treatment Juvista.

Dermatology Wound Healing & Tissue Repair
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Therapeutic Areas
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Angiotech Pharmaceuticals Inc.
  • Senior Management
  • Joseph Galli, CEO
    Lyne Pare, Dir., Fin. & Admin.
  • Contact Info
  • Haemacure Corp.
    Phone: (514) 282-3350
    215 Redfern Ave.
    Ste. 100
    Montreal, H3Z 3L5
    Canada
UsernamePublicRestriction

Register